Importantly, in 7-day co-cultures of healthy donor-derived PBMCs (i.e., non-enriched, non-preactivated type 1 NKT and Vγ9Vδ2-T cells) and tumor cell lines, AML growth was controlled and MM growth further reduced in the presence of the CD1d-Vδ2 bsTCE even at low to very low E:T ratios (Figure 3A). This evidence concerns the gene CD1D and Miyoshi myopathy.